KUSUDAMA Therapeutics SL is a technology-based spin-off from CIDETEC, one of the most important private technology centres in the Basque Country. The company’s objective is to develop new drug formulations for the treatment of a variety of pulmonary conditions.
OUR PROJECT
Our technology is based on the nanomedicine platform known as KuDa, developed by CIDETEC. The technology is patented in the European Union and in the United States. The nanomedicine platform is based on a new methodology for manufacturing single chain nanoparticles (SCNP) in an aqueous medium at room temperature and in the absence of catalysts, by cross-linking the polymer chain with a bifunctional agent.
The platform is designed to develop new products in the area of respiratory diseases. Due to its physical-chemical properties and size (15-40 nanometres), it will be able to remain in the lungs for longer periods of time and achieve greater penetration of the pulmonary mucus.
It is a versatile platform that allows various active ingredients to be included by means of electrostatic or covalent interactions. The particles are suitable for administration by nebulisation.
MAIN ADVANTAGES
KuDa directs the active ingredient, increasing its efficacy.
KUSUDAMA
The company is headed by a first-rate team with experience in drug development, venture capital and licensing, which will ensure an efficient management focused on product development.
Fermín Goytisolo
Chief Executive Officer (CEO)
fgoytisolo@kusudama.eu
Xabier Murgia
Chief Scientific Officer (CSO)
xmurgia@kusudama.eu
The company is headed by a first-rate team with experience in drug development, venture capital and licensing, which will ensure an efficient management focused on product development.
CONTACT
Parque Científico y Tecnológico de Gipuzkoa
Pº Miramón, 196
20014 Donostia – San Sebastián
Kusudama 2019